No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Express News | Tianda Pharmaceuticals - Unit Granted Drug Registration Approval of Ibuprofen Suspension by Nmpa
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Tianda Pharmaceutical (00455): “Nicodyl for injection” obtained drug registration certificate
According to the Zhitong Finance App, Tianda Pharmaceutical (00455) issued an announcement. Tianda Pharmaceutical (Yunnan) Co., Ltd. (Yunnan Pharmaceutical), a wholly-owned subsidiary of the company, has obtained a drug registration certificate for “injectable nicordil” issued by the China National Drug Administration. The main component of this product is nicordil, which is a freeze-dried powder injection form. Its indications are mainly acute coronary syndrome such as unstable angina pectoris. Nicordil is a first-line medication for coronary microvascular angina pectoris. It can effectively dilate the coronary arteries and works quickly. It has been included in the “Guidelines for Appropriate Use of Coronary Artery Disease (2nd Edition)” and “Non-ST Segment Elevation Emergency
No Data